On Mar. 15, 2020, Fosun Pharma and BioNTech announced a strategic development and commercialization collaboration to advance BioNTech’s mRNA vaccine in China for the prevention of COVID-19 infections.

Under the terms of the agreement, the companies collaborated to conduct clinical trials in China leveraging Fosun Pharma’s extensive clinical development, regulatory, and commercial capabilities in the country. BioNTech will supply the mRNA vaccine for clinical trials from GMP manufacturing facilities in Europe.